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ABSTRACT Purpose. The objective of this study was
to evaluate a dual action prodrug concept wherein an
unnatural myristic acid analogue is coupled via an
ester moiety to the 5’-position of FLT or AZT.
Subsequent intracellular cleavage of the prodrug ester
would simultaneously release FLT or AZT that could
inhibit reverse transcriptase (RT), and the myristic
acid analogue that could inhibit myristoyl-
CoA:protein N-myristoyltransferase (NMT).
Methods: Cytotoxicity (2.2.15 cell culture), and anti-
hepatitis B activity of 5’-O-myristoyl analogue
prodrug derivatives of FLT and AZT (2-8) were
evaluated in vitro using human liver hepatitis B virus
(HBV) producing 2.2.15 cell lines. Results: The 5’-
O-(12-methoxydodecanoyl) ester derivatives of AZT
(2, EC50 = 2.7 –  0.3 m M; CC50 = 727 –  19 m M) and
FLT (4, EC50 = 2.8 –  0.3 m M; CC50 = 186 –  20 m M)
were the most effective anti-hepatitis B virus (anti-
HBV) compounds of this series in a replication assay.
In the series of 5’-O-myristic acid analogue ester
prodrug derivatives of FLT, the relative anti-HBV
potency order was MeO(CH2)11CO2- >
N3(CH2)11CO2- and Br(CH2)11CO2- > EtS(CH2)nCO2-
(n = 10 or 11) > Me(CH2)12CO2- (myristoyl).
Conclusions: The in vitro data suggest that the 5’-O-
myristoyl analogue prodrug concept offers a potential
drug design approach to design dual acting antiiviral
agents, with superior pharmacokinetic,
biodistribution, reduced cytotoxicity and/or increased
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efficacy. In this regard, the 5’-O-(12-
methoxydodecanoyl) prodrug ester of 3’-thia-3’-
deoxythymidine (3TC) may offer the greatest
potential for the treatment of HBV infection.
INTRODUCTION
Five percent of the world population, or over 300
million people, are chronically infected with hepatitis
B virus (HBV) (1). Troisi et al. (2) reported that 75%
of human immunodeficiency virus (HIV) seropositive
men also showed evidence of HBV infection. One
notable similarity between these two human
pathogenic viruses is that their replicative cycles
involve an obligate RNA intermediate and a reverse
transcription step in the cytoplasm. HBV contains a
specific DNA polymerase, that is vital for replication,
which acts as a reverse transcriptase during the
replication of HBV DNA via an RNA intermediate
(3).
Although vaccination has been used for the
prevention of HBV infection, there are no clinically
effective drugs available for the treatment of HBV
infection. Recently, (-)-b -2’,3’-dideoxy-3’-
thiacytidine (3TC), which has been the subject of
clinical trials in HBV-infected patients (4), and 2’,3’-
dideoxycytidine (ddC) were shown to be potent
inhibitors of hepatitis B virus replication in vitro (5).
However, long-term ddC administration causes
delayed toxicity such as peripheral neuropathy in
patients, which was attributed to depletion of
mitochondrial DNA in host cells (6). Since HBV
causes severe and often fatal side effects, there is an
urgent need to design novel and effective drugs with
low host toxicity. The in vitro anti-HBV activities for
5’-O-myristoyl analogue derivatives of AZT and FLT
(2-8) were investigated in this study (Tables 1 and 2).
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Table 1. Relative in vitro potency and selectivity of 5’-O-myristoyl analogue derivatives of FLT and AZT as inhibitors of
HBV DNA replication in 2.2.15 cell culture (HBV virion extracellular DNA).
No. R1 R2 CC50 (µM)a EC50 (µM)b EC90 (µM)c SId
2 MeO(CH2)11CO N3 727 ± 19 2.7 ± 0.3 17 ± 1.8 43
3 Br(CH2)11CO F 417 –  38 8.0 ± 1 48 ± 7.8 8.7
4 MeO(CH2)11CO F 186 ± 20 2.8 ± 0.3 8.1 ± 1.2 23
5 EtS(CH2)11CO F 193 ± 14 21 ± 2 50 ± 5 3.9
6 EtS(CH2)10CO F 275 ± 23 22 ± 2 51 ± 6 5.4
7 CH3(CH2)12CO F 384 –  25 >30 >30 ND
8 N3(CH2)11CO F 61 ± 6 6.1 ± 1.4 18 ± 2 3.4
FLTe H F 361 –  24 ¾ 40 –  4 9
ddCf 252 ± 28 1.3 ± 0.1 6.8 ± 0.7 37
3TCg 1180 –  125 0.033 –  0.004 0.188 –  0.02 6280
1h MeO(CH2)11COOH 379 –  22 22 ± 1.8 60 ± 6.3 6.3
aCC50 = 50% cytotoxic concentration. bEC50 = 50% effective concentration. cEC90 = 90% effective
concentration.dSelectivity Index (S.I.: CC50 /EC90). eData taken from Korba et al. (22). fddC = 2’,3’-
dideoxycytidine. gData taken from Xie et al. (25). hData taken from Parang et al. (9).
These ester prodrugs were designed with the
expectation that two anti-HBV agents (nucleoside
and myristic acid analogue) would be released upon
ester cleavage of the prodrug. The parent nucleoside
(FLT or AZT) and the myristic acid analogue have
different biochemical targets thereby increasing the
probability of enhanced anti-HBV efficacy. This
approach includes inhibition of reverse transcriptase
by FLT and AZT, and inhibition of myristoyl-
CoA:protein N-myristoyltransferase (NMT) that
catalyzes the myristoylation of viral proteins by the
myristic acid analogue (7). Myristoylation by
unnatural myristic acid analogues may block the
synthesis of the PreS1 protein in the membrane
envelope of HBV (8). 12-Methoxydodecanoic acid
(1), a myristic acid analogue, was previously reported
to be a moderately active inhibitor of HBV DNA
replication in 2.2.15 cell culture [HBV DNA
replication intermediates (HBV RI intracellular
DNA), HBV virion extracellular DNA] compared to
the reference compound ddC and it was less toxic (9).
Although myristoylation-null HBV mutants form
virion particles, these particles are non-infectious (8).
N
NH
O
O
Me
O
R2
R1O
2-8
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Table 2. Relative in vitro potency and selectivity of 5’-O-myristoyl analogue derivatives of FLT and AZT as inhibitors of
HBV DNA replication in 2.2.15 cell culture [HBV replication intermediate (RI) intracellular DNA].
No. R1 R2 CC50 (µM)a EC50 (µM)b EC90 (µM)c SId
2 MeO(CH2)11CO N3 727 ± 19 4.9 ± 0.5 27 ± 2.9 27
3 Br(CH2)11CO F 417 –  38 19 ± 2.1 78 ± 7.8 5.3
4 MeO(CH2)11CO F 186 ± 20 5.6 ± 0.6 17 ± 1 11
5 EtS(CH2)11CO F 193 ± 14 34 ± 4 86 ± 8 2.2
6 EtS(CH2)10CO F 275 ± 23 33 ± 4 70 ± 8 3.9
7 CH3(CH2)12CO F 384 –  25 >30 >30 ND
8 N3(CH2)11CO F 61 ± 6 11 ± 2 28 ± 3 2.2
FLTe H F 361 –  24
¾
40 –  4 9
AZTe H N3 ¾ > 100 ¾ ¾
ddCf 252 ± 28 2.6 ± 0.3 13 ± 1.8 19
3TCg 1180 0.076 –  0.008 0.29 –  0.03 4030
1h MeO(CH2)11COOH 379 –  22 31 ± 3.4 90 ± 11 4.2
aCC50 = 50% cytotoxic concentration. bEC50 = 50% effective concentration. cEC90 = 90% effective concentration.dSelectivity
Index (S.I.: CC50 /EC90). eData taken from Korba et al. (22). fddC = 2’,3’-dideoxycytidine. gData taken from Xie et al. (25).
hData taken from Parang et al. (9).
Although AZT and FLT exhibit in vitro anti-HIV
activity (10), data from clinical trials in HIV-
seropositive patients suggested that FLT induced
severe toxic effects such as thrombocytopenia and
anemia, providing a narrow therapeutic window (11)
that resulted in the termination of clinical trials. 5’-O-
Myristoyl analogue prodrugs of FLT may have a
number of potential advantages relative to FLT,
including (i) a reduction in the toxicity of FLT, (ii)
two different mechanisms of action for greater
therapeutic efficacy, and (iii) the myristic acid
analogue moiety does not induce bone marrow
toxicity. Further, to treat hepatitis B more effectively,
it would be desirable to deliver a larger percentage of
the antiviral nucleoside dose to the liver. It was
anticipated that the lipophilic 5’-O-myristic acid
analogue prodrugs (2-8) would undergo extensive
hepatic uptake since the non-polar myristoyl
analogue ester moiety increases lipophilicity. The
parent nucleosides, AZT and FLT, also exhibit in
vitro anti-HIV activity (10). Since multiple
concomitant viral infections frequently occur, there
would be a potential clinical benefit to treat both
HBV and HIV infections using a single drug.
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FLT is one of the most effective antiviral agents in
vitro, producing a greater than 90% reduction (0.03
m M) in HBV DNA synthesis. FLT 5’-triphosphate is
a potent inhibitor of endogenous HBV DNA
polymerase, preventing the formation of HBV in
HepG2 cells transfected with HBV DNA in vitro
(12). In contrast, AZT failed to suppress the
replication of HBV in patients with HIV and HBV
infection (13-15) and was relatively ineffective
against HBV replication in 2.2.15 cells even at the
highest possible concentration (20 m M) that did not
affect cellular growth (5, 16). AZT had no
appreciable effects on HBV DNA replication in HIV
patients with chronic hepatitis B infection, during
long term therapy (13) and it did not inhibit HBV
DNA polymerase as determined from in vitro assays.
Since AZT is metabolized in the liver (17), effective
levels of the active triphosphate may not be present in
hepatocytes even though AZT-triphosphate (AZT-
TP) inhibits HBV DNA polymerase in vitro (EC50 =
0.15 m M) (18). The action of AZT against HBV
appears to be related to inhibition of HBV DNA
polymerase (18).
MATERIALS AND METHODS
Chemistry
12-Methoxydodecanoic acid (1) (7), 3’-azido-2’,3’-
dideoxythymidine (AZT) (19) and 3’-fluoro-2’,3’-
dideoxythymidine (FLT) (10) were prepared
according to literature methods. The 5’-OH of AZT
(1.3 mmol) was esterified using 12-
methoxydodecanoic acid (1) (1.3 mmol) in anhydrous
benzene (18 mL) in the presence of oxalyl chloride
(1.9 mmol) and 4-(dimethylamino)pyridine (DMAP)
(1.9 mmol) to yield 3’-azido-2’,3’-dideoxy-5’-O-(12-
methoxydodecanoyl)thymidine (2) in 56% yield (20).
A similar procedure was used for the preparation of
the 5’-O-myristoyl analogue derivatives of FLT (3-7)
(21). Further reaction of 3’-fluoro-2’,3’-dideoxy-5’-
O-(12-bromododecanoyl)thymidine (3) with sodium
azide at room temperature in dimethyl formamide
produced the corresponding 12-azido analog (8) (21).
In Vitro Anti-HBV Assays
Two assay methods were used to determine anti-
HBV activity. These two assays differ in the duration
of exposure, harvesting time, and the method used to
detect HBV DNA (direct beta scanner in NIH method
versus dot blot hybridization in our laboratory).
The first assay (results shown in Tables 1 and 2) used
to measure anti-HBV activity in cultures of 2.2.15
cells was performed by the screening service
provided by the United States National Institutes of
Health (NIH) (5). Briefly, chronically HBV-
producing human liver cells were seeded into 24-well
tissue culture plates and grown to confluence. Test
compounds were then added daily for a continuous 9
day period. Culture medium (changed daily during
the treatment period) was collected and stored for
analysis of extracellular (virion) HBV DNA after 0,
3, 6, and 9 days of treatment. Treated cells were lysed
for 24 hours following day 9 of treatment for the
analysis of intracellular HBV genomic forms. HBV
DNA was then analyzed in a quantitative and
qualitative manner for overall levels of HBV DNA
(both extracellular and intracellular DNA) and the
relative rate of HBV replication (intracellular DNA).
Analysis of HBV DNA was performed using blot
hybridization techniques (southern and slot blot) and
[32P]-labelled HBV-specific probes. HBV DNA
levels were measured by comparison to known
amounts of HBV DNA standards applied to each
nitrocellulose membrane (gel or slot blot). An
AMBIS beta scanner, which measures the radioactive
decay of the hybridized probes directly on the
nitrocellulose membranes, was used for quantitative
analysis. HBV DNA levels were then compared to
those at Day 0 to determine the effect of drug
treatment (see Table 1).
The second assay used HBV-producing 2.2.15 cell
cultures derived from a human hepatoblastoma cell
line (Hep G2) together with the dot hybridization
technique, as previously described (9). Viral
replication (the values are the average of two
different experiments) was estimated from the
amount of HBV DNA present in the supernatant of
the cell culture after incubation with the test
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compound (10 m g/mL, 19.8-22.0 m M range for 3-7).
The data are expressed as a percentage of control
values where the cell culture was not incubated with
the test compound. The percentage of DNA
replication in presence of the test compound was
calculated using the following relationship:
[Sample (treated 2.2.15 sample) - Negative Control
(HepG2)] ·  100 / [Untreated 2.2.15 Positive Control
- Negative Control (HepG2)] = % replication (see
Table 2).
Cytotoxicity Assay
Cytotoxicity induced by the test compounds in
cultures of 2.2.15 cells was also determined by the
United States NIH (22). Briefly, 2.2.15 cells were
grown to confluence in 96 well flat-bottomed tissue
culture plates and treated with test compound (in 0.2
mL culture medium/well) as described above. Four
concentrations of each test compound were assayed,
each in triplicate cultures, in 3 to 10-fold dilution
steps. Untreated control cultures were maintained on
each 96 well plate. On each 96 well plate, wells
containing no cells were used to correct for light
scattering. Toxicity was determined by measuring
neutral red dye uptake, as determined from the
absorbance at 510 nm relative to untreated cells, at 24
hours following day 9 of treatment (see Tables 1 and
2).
RESULTS AND DISCUSSION
Anti-HBV activities from the first assay for selected
analogues are summarized in Tables 1 (HBV virion
extracellular DNA) and 2 (HBV replication
intermediate intracellular DNA). The prodrug esters
(2-8) were designed to act as anti-HBV agents after
the release of AZT or FLT which would inhibit
reverse transcriptase and, at least in part, to the anti-
HBV effect of the myristic acid analogue produced
after cleavage of the prodrug.
3’-Azido-2’,3’-dideoxy-5’-O-(12-
methoxydodecanoyl)thymidine (2) exhibited
comparable potency to 2',3'-dideoxycytidine (ddC),
and the selectivity indexes (SI) were similar.
Although AZT is one of the least effective
nucleosides against HBV replication in 2.2.15 cells,
the 5’-O-(12-methoxydodecanoyl) ester (2) showed
comparable activity (EC50 = 2.7 –  0.3 m M) to ddC
(EC50 = 1.3 ± 0.1 m M) and it was less cytotoxic (CC50
= 727 –  19 m M) than ddC (CC50 = 228 ± 2.8 m M)
(Table 1). The precise basis for the increased activity
of 2 relative to the inactive AZT (EC50 > 100 m M)
against HBV is unknown, but it could be due to an
increased intracellular concentration of 2, due to its
enhanced ability to cross the cell membrane by
passive difusion and/or a higher concentration of
AZT produced from 2, in infected cells. Horrobin et
al. (23) observed that g -linoleic acid-AZT (GLA-
AZT) also inhibited herpesvirus replication, a
property not found with either GLA or AZT
individually. Further studies are required to
determine whether the enhanced anti-HBV activity
exhibited by 2 (log P = > 5) (20), relative to AZT (log
P = 0.11) (21), is due to increased cellular uptake
and/or facile intracellular prodrug conversion to
AZT.
3’-Fluoro-2’,3’-dideoxy-5’-O-(12-
methoxydodecanoyl)thymidine (4) exhibited the
highest anti-HBV activity (EC50 = 5.6 m M) among
the 3’-fluoro analogs tested (3-8). Although 4 was
approximately equiactive to 2, it was more cytotoxic
than 2 (Tables 1, 2), probably due to differences in
partition coefficient, rate of intracellular ester
cleavage and/or cellular uptake. It was previously
reported that 12-methoxydodecanoic acid (1)
exhibited weaker anti-HBV activity and was less
toxic than ddC (9). This structure-activity
relationship demonstrates the contribution of 12-
methoxydodecanoic acid with respect to the activity
exhibited by the 5’-O-12-methoxydodecanoate esters
2 and 4, which were the most potent analogues tested
of the prodrugs 2-8 investigated (Tables 1, 2).
Although the 5’-O-(12-methoxydodecanoyl) ester
derivatives of AZT and FLT (2, 4) have similar
selectivity indexes (SI = 23-43 m M) to FLT (SI = 9)
in vitro, the parenteral administration of myristoyl
analogue ester prodrugs of antiviral nucleosides may
increase in vivo efficacy and selectivity due to
improved pharmacokinetic and/or biodistribution
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properties that are relevant to FLT therapy for
treatment of hepatitis B infection. There is credence
for this assumption since it was previously reported
that incubation of the myristoyl ester analogues 3-8 at
37°C with porcine liver esterase (t1/2 = 1.9-20.3 min
range), rat plasma (t1/2 = 0.8-4.6 min range) and rat
brain homogenate (t1/2 = 11.7-21.9 min range)
possess variable enzymatic stabilities. Myristoyl ester
analogues 3-8 are very lipophilic (log P = 4.3 to > 5
range) relative to AZT (log P = 0.11) and FLT (log P
= -0.30) (21).
The stability of 5’-O-(12-azidododecanoyl)thymidine
in the cell culture medium was previously reported
(24) following incubation with RPMI 1640/10% FBS
at a concentration of 1 mM at 37°C. This in vitro cell
culture control incubation study showed that 5’-O-
(12-azidododecanoyl)thymidine was relatively stable
with a half-life of eight days. Therefore, it is
postulated that similar prodrugs (2-8) may exist as
intact esters extracellularly in the in vitro anti-HBV
assay (20, 24). The differences in anti-HBV activity
exhibited by the 5’-O-myristoyl analogue derivatives
of FLT (3-8) could be due to several factors such as
their uptake rate into cells, their rate of intracellular
conversion to FLT, and differences in the anti-HBV
activity among the myristic acid analogue released
after ester cleavage.
Some myristoyl analog ester prodrugs (3-7) were
evaluated in a second assay against HBV in 2.2.15
cell cultures derived from a human hepatoblastoma
cell line (Hep G2). At a test compound concentration
in the 19.8-22.0 m M range for compounds 3-7 (10
m g/mL), none of these esters significantly inhibited
the replication of HBV-infected hepatocytes
compared to FLT or 3TC. The % of viral replication
for selected compounds [compound number (% of
viral replication)] was 3 (57.6%); 4 (91.2%); 5
(88.1%); 6 (87.7%), 7 (85.4%); FLT (10.8%); 3TC
(0.0%) and control (100.0%). The relative anti-HBV
activities of some compounds such as FLT, 3-4 and
5-6 in these two assays are different when compared
to the their corresponding EC90 values in Table 1,
since the harvesting time, the duration of exposure,
and the time at which cells were exposed to the test
compound, differ. These results indicate that
evaluation in one cell culture system may not provide
representative antiviral activity data.
Additional studies are required to make definitive
conclusions regarding the anti-HBV effects exhibited
by these myristoyl prodrug compounds. The data
acquired indicate that these lipophilic prodrugs of
AZT and FLT may offer a method to increase in vivo
efficacy and selectivity of nucleoside therapy to treat
hepatitis B infection. The exact mode of action of 5’-
O-myristoyl analogue derivatives of AZT and FLT
will obviously remain speculative until further
mechanistic investigations have been carried out. The
evaluation of 5’-O-myristoyl analogue derivatives of
more active nucleoside analogues such as 3TC may
provide additional evidence regarding the potential
value of this prodrug design concept.
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